Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10060311HBVENSG00000171105.14protein_codingINSRYesNo3643P06213
TVIS30087023HIVENSG00000171105.14protein_codingINSRYesNo3643P06213
TVIS30074133HIVENSG00000171105.14protein_codingINSRYesNo3643P06213
TVIS20007384HPVENSG00000171105.14protein_codingINSRYesNo3643P06213
TVIS20007385HPVENSG00000171105.14protein_codingINSRYesNo3643P06213
TVIS20004195HPVENSG00000171105.14protein_codingINSRYesNo3643P06213
TVIS20065658HPVENSG00000171105.14protein_codingINSRYesNo3643P06213
TVIS20043075HPVENSG00000171105.14protein_codingINSRYesNo3643P06213
TVIS20024956HPVENSG00000171105.14protein_codingINSRYesNo3643P06213
TVIS20034877HPVENSG00000171105.14protein_codingINSRYesNo3643P06213
TCGA Plot Options
Drug Information
GeneINSR
DrugBank IDDB16637
Drug NameKW-2450 free base
Target IDBE0000033
UniProt IDP06213
Regulation Typeinhibitor
PubMed IDs30083253
CitationsUmehara H, Maekawa Y, Koizumi F, Shimizu M, Ota T, Fouad TM, Willey J, Kaito H, Shiraishi N, Nakashima D, Akinaga S, Ueno NT: Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole. Ther Adv Med Oncol. 2018 Jul 30;10:1758835918786858. doi: 10.1177/1758835918786858. eCollection 2018.
GroupsExperimental
Direct Classification
SMILESCC1=C(SC=C1)C(=O)NC1=CC(CN2CCN(CC2)C(=O)CO)=CC=C1C=CC1=NNC2=CC=CC=C12
Pathways
PharmGKB
ChEMBL